File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Indolent T-cell large granular lymphocyte leukaemia after haematopoietic SCT: A clinicopathologic and molecular analysis
  • Basic View
  • Metadata View
  • XML View
TitleIndolent T-cell large granular lymphocyte leukaemia after haematopoietic SCT: A clinicopathologic and molecular analysis
 
AuthorsGill, H1
Ip, AHW1
Leung, R1
So, JCC1
Pang, AWK1
Tse, E1
Leung, AYH1
Lie, AKW1
Kwong, YL1
 
Keywordsallogeneic
autologous
haematopoietic SCT
indolent
T-cell large granular lymphocyte leukaemia
 
Issue Date2012
 
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
 
CitationBone Marrow Transplantation, 2012, v. 47 n. 7, p. 952-956 [How to Cite?]
DOI: http://dx.doi.org/10.1038/bmt.2011.212
 
AbstractFour women and three men after allogeneic (n4) and autologous (n3) haematopoietic SCT (HSCT) were observed to have an increase in T-cell large granular lymphocytes (T-LGLs) of CD3CD8 phenotype for a median of 41 (15-118) months. Clonal rearrangement of the T-cell receptor gene was verified by two PCR techniques and direct DNA sequencing, confirming that the cases were neoplastic and therefore classifiable as T-LGL leukaemia. In the allogeneic HSCT cases, T-LGL leukaemia was derived from donor T cells in three patients, as shown by DNA chimerism analysis, and recipient T cells in one patient who had graft failure previously. None of the patients showed cytopenia, autoimmune phenomenon or organ infiltration, which were features typical of de novo T-LGL leukaemia. Six patients had remained asymptomatic with stable large granular lymphocyte counts. One patient died from cerebral relapse of the original lymphoma. T-LGL leukaemias occurring post-HSCT are distinct from de novo T-LGL leukaemia and may have a different pathogenesis and clinical course. Patients did not require specific treatment, and the disease remained stable for long periods. © 2012 Macmillan Publishers Limited.
 
ISSN0268-3369
2013 Impact Factor: 3.466
2013 SCImago Journal Rankings: 1.441
 
DOIhttp://dx.doi.org/10.1038/bmt.2011.212
 
ISI Accession Number IDWOS:000306113100008
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorGill, H
 
dc.contributor.authorIp, AHW
 
dc.contributor.authorLeung, R
 
dc.contributor.authorSo, JCC
 
dc.contributor.authorPang, AWK
 
dc.contributor.authorTse, E
 
dc.contributor.authorLeung, AYH
 
dc.contributor.authorLie, AKW
 
dc.contributor.authorKwong, YL
 
dc.date.accessioned2012-05-29T06:14:24Z
 
dc.date.available2012-05-29T06:14:24Z
 
dc.date.issued2012
 
dc.description.abstractFour women and three men after allogeneic (n4) and autologous (n3) haematopoietic SCT (HSCT) were observed to have an increase in T-cell large granular lymphocytes (T-LGLs) of CD3CD8 phenotype for a median of 41 (15-118) months. Clonal rearrangement of the T-cell receptor gene was verified by two PCR techniques and direct DNA sequencing, confirming that the cases were neoplastic and therefore classifiable as T-LGL leukaemia. In the allogeneic HSCT cases, T-LGL leukaemia was derived from donor T cells in three patients, as shown by DNA chimerism analysis, and recipient T cells in one patient who had graft failure previously. None of the patients showed cytopenia, autoimmune phenomenon or organ infiltration, which were features typical of de novo T-LGL leukaemia. Six patients had remained asymptomatic with stable large granular lymphocyte counts. One patient died from cerebral relapse of the original lymphoma. T-LGL leukaemias occurring post-HSCT are distinct from de novo T-LGL leukaemia and may have a different pathogenesis and clinical course. Patients did not require specific treatment, and the disease remained stable for long periods. © 2012 Macmillan Publishers Limited.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationBone Marrow Transplantation, 2012, v. 47 n. 7, p. 952-956 [How to Cite?]
DOI: http://dx.doi.org/10.1038/bmt.2011.212
 
dc.identifier.citeulike9986536
 
dc.identifier.doihttp://dx.doi.org/10.1038/bmt.2011.212
 
dc.identifier.epage956
 
dc.identifier.hkuros205184
 
dc.identifier.isiWOS:000306113100008
 
dc.identifier.issn0268-3369
2013 Impact Factor: 3.466
2013 SCImago Journal Rankings: 1.441
 
dc.identifier.issue7
 
dc.identifier.pmid22041849
 
dc.identifier.scopuseid_2-s2.0-84863721430
 
dc.identifier.spage952
 
dc.identifier.urihttp://hdl.handle.net/10722/148652
 
dc.identifier.volume47
 
dc.languageeng
 
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofBone Marrow Transplantation
 
dc.relation.referencesReferences in Scopus
 
dc.subjectallogeneic
 
dc.subjectautologous
 
dc.subjecthaematopoietic SCT
 
dc.subjectindolent
 
dc.subjectT-cell large granular lymphocyte leukaemia
 
dc.titleIndolent T-cell large granular lymphocyte leukaemia after haematopoietic SCT: A clinicopathologic and molecular analysis
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Gill, H</contributor.author>
<contributor.author>Ip, AHW</contributor.author>
<contributor.author>Leung, R</contributor.author>
<contributor.author>So, JCC</contributor.author>
<contributor.author>Pang, AWK</contributor.author>
<contributor.author>Tse, E</contributor.author>
<contributor.author>Leung, AYH</contributor.author>
<contributor.author>Lie, AKW</contributor.author>
<contributor.author>Kwong, YL</contributor.author>
<date.accessioned>2012-05-29T06:14:24Z</date.accessioned>
<date.available>2012-05-29T06:14:24Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Bone Marrow Transplantation, 2012, v. 47 n. 7, p. 952-956</identifier.citation>
<identifier.issn>0268-3369</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/148652</identifier.uri>
<description.abstract>Four women and three men after allogeneic (n4) and autologous (n3) haematopoietic SCT (HSCT) were observed to have an increase in T-cell large granular lymphocytes (T-LGLs) of CD3CD8 phenotype for a median of 41 (15-118) months. Clonal rearrangement of the T-cell receptor gene was verified by two PCR techniques and direct DNA sequencing, confirming that the cases were neoplastic and therefore classifiable as T-LGL leukaemia. In the allogeneic HSCT cases, T-LGL leukaemia was derived from donor T cells in three patients, as shown by DNA chimerism analysis, and recipient T cells in one patient who had graft failure previously. None of the patients showed cytopenia, autoimmune phenomenon or organ infiltration, which were features typical of de novo T-LGL leukaemia. Six patients had remained asymptomatic with stable large granular lymphocyte counts. One patient died from cerebral relapse of the original lymphoma. T-LGL leukaemias occurring post-HSCT are distinct from de novo T-LGL leukaemia and may have a different pathogenesis and clinical course. Patients did not require specific treatment, and the disease remained stable for long periods. &#169; 2012 Macmillan Publishers Limited.</description.abstract>
<language>eng</language>
<publisher>Nature Publishing Group. The Journal&apos;s web site is located at http://www.nature.com/bmt</publisher>
<relation.ispartof>Bone Marrow Transplantation</relation.ispartof>
<subject>allogeneic</subject>
<subject>autologous</subject>
<subject>haematopoietic SCT</subject>
<subject>indolent</subject>
<subject>T-cell large granular lymphocyte leukaemia</subject>
<title>Indolent T-cell large granular lymphocyte leukaemia after haematopoietic SCT: A clinicopathologic and molecular analysis</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1038/bmt.2011.212</identifier.doi>
<identifier.pmid>22041849</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84863721430</identifier.scopus>
<identifier.hkuros>205184</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84863721430&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>47</identifier.volume>
<identifier.issue>7</identifier.issue>
<identifier.spage>952</identifier.spage>
<identifier.epage>956</identifier.epage>
<identifier.isi>WOS:000306113100008</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>9986536</identifier.citeulike>
</item>
Author Affiliations
  1. Queen Mary Hospital Hong Kong